To The Moon

1. Pharma stocks $Regeneron Pharmaceuticals(REGN)$ and $Vertex Pharmaceuticals(VRTX)$ hit new high of $853.97 and $374.45 respectively. $Regeneron Pharmaceuticals(REGN)$ three core value drivers are its eye disease drug Eylea (now available in a high-dose form), immunology drug Dupixent, and anti-cancer therapy Libtayo. FDA approved its high-dose Eylea in August. $Vertex Pharmaceuticals(VRTX)$ is striving to develop treatments for APOL1-mediated kidney disease, non-opioid pain medications, rare blood disorders, and diabetes. 2. Insurance stocks $Arch Capital(ACG

Analyzing the Expected Move of Tesla After Earnings and a Neutral Options Strategy - The Iron Condor Expected Move of TSLA on Oct 20. As $Tesla Motors(TSLA)$ gears up for its earnings announcement, investors and traders are closely watching the stock's expected price movement. Market volatility often surges around earnings reports, presenting opportunities for those willing to explore options strategies. In this post, let’s delve into the expected move for Tesla and discuss a neutral options strategy - the Iron Condor - that could help you benefit from the earnings release. Expected Move for Tesla After Earnings According to options pricing, the market is anticipating an expected move of approximately 4.9% for Tesla follo

On Fri, 13 Oct 2023 — $JPMorgan Chase(JPM)$, $Wells Fargo(WFC)$ and $Citigroup(C)$ have released their Q3 2023 earnings. Despite all the challenges faced by the financial sector, the 3 banks managed to report profits. JPMorgan Chase & Co. reported a profit of $13.15 billion, or $4.33 a share, YoY. Wells Fargo & Company reported a profit of $6.04 billion, or $1.38 a share, YoY. Citigroup Inc.reported a profit of $5.2 billion, or $2.85 a share, YoY. On Tue, 17 Oct 2023 $Bank of America(BAC)$ will be reporting its Q3 2023 quarterly earnings. I came across a post by Barron (see below), that I think is insightful and remind

Hello, fellow tigers! Today, I want to share how I celebrated $Bank of America(BAC)$ recent third-quarter earnings report with a well-timed strangle position. Q3 Highlights In the third quarter, BAC reported earnings per share (EPS) of $0.90, surpassing the analyst consensus estimate of $0.83. Additionally, the bank's revenue for the quarter came in at $25.2 billion, slightly ahead of the consensus estimate of $25.13 billion. These impressive results provided a strong foundation for my investment strategy. BAC Daily Chart With the stock price that closed at $26.99, it's important to note that BAC had faced some challenges, with a -14.83% decline over the last three months and a -22.62% dip in the past year. Despite these hurdles, I saw an opportuni